美国米利亚德基因Myriad Genetics
Myriad Genetics成立于1991年,使用以基因医学来开发医疗及分子诊断产品。他们利用多种专有proteomic技术来发现疾病基因并了解这些基因在疾病的产生与发展中所起的作用。他们综合使用生物信息及机器人系统来进行他们的高效能科研。这种做法使他们已辨认了许多作爲新药目标级分子诊断的蛋白质。
  

 



Founded in 1991, Myriad Genetics soon emerged as a world leader in the new field of molecular diagnostics. In addition to its molecular diagnostics business, Myriad has a strong drug development pipeline, Going forward, Myriad is uniquely positioned to develop and commercialize new molecular diagnostics and pharmaceuticals that prevent or mitigate the toll of mankind's deadliest diseases.

Pharmaceuticals
Myriad Pharmaceuticals is an organization with capabilities ranging from the identification of novel drug targets, discovery of lead molecules, development of drug candidates and finally, to designing and executing clinical programs. We believe our strategy is a model for success in the biopharmaceutical industry. We focus on disease areas for which there is a large, unmet medical need and we apply a novel approach to therapeutic development based on new technologies and new ways of looking at drug development problems.